These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3855599)

  • 1. Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia.
    Kirshner J; Preisler HD; Raza A
    Am J Hematol; 1985 Feb; 18(2):191-200. PubMed ID: 3855599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase.
    Preisler HD; Kirshner J
    Exp Hematol; 1983 Aug; 11(7):618-25. PubMed ID: 6576910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Varying course of pancytopenia after busulfan treatment of chronic myelocytic leukemia (CML)].
    Krug K; Stenzel L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1978; 105(2):181-7. PubMed ID: 79522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival in Ph1-positive chronic myelocytic leukemia: relationship to findings at diagnosis and to disease kinetics after the first course of treatment.
    Gomez GA; Reese PA; Sokal JE
    Leuk Res; 1985; 9(5):633-40. PubMed ID: 3859712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total body irradiation in chronic myeloid leukemia.
    Advani SH; Dinshaw KA; Nair CN; Ramakrishnan G
    Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):497-500. PubMed ID: 6343310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
    Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ
    Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
    Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
    Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy of chronic myelocytic leukemia.
    Galton DA
    Semin Hematol; 1969 Oct; 6(4):323-43. PubMed ID: 4900650
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents.
    Spiro TE; Mattelaer MA; Efira A; Stryckmans P
    J Natl Cancer Inst; 1981 Jun; 66(6):1053-9. PubMed ID: 6941040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B.
    Silver RT; Mick R; Cooper R; Ellison RR; Levy R; Brunner K; Schwartz JM; Holland JF
    Cancer; 1987 Oct; 60(7):1442-8. PubMed ID: 3113712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan, antimetabolites, radiotherapy, and cost of treatment in chronic myelocytic leukemia. A non-controlled, non-randomized monocenter study with historical controls.
    Ogier C; Reizenstein P
    Acta Med Scand; 1981; 210(5):409-13. PubMed ID: 6950660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Course and prognosis of chronic myeloid leukemia treated with busulfan. Study of 300 cases].
    Ionescu V
    Dtsch Med Wochenschr; 1971 May; 96(20):867-70. PubMed ID: 5280862
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical picture of myelocytic leukemia in children, drug sensitivity tests and DNA histograms].
    Rytwiński K; Wójcik Z; Sońta-Jakimczyk D; Sroczyńska M
    Acta Haematol Pol; 1985; 16(3-4):170-8. PubMed ID: 3869773
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
    Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
    Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial in vitro bone marrow fibroblast culture in human leukemia.
    Nagao T; Yamauchi K; Komatsuda M
    Blood; 1983 Mar; 61(3):589-92. PubMed ID: 6572079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agar culture studies in CML and blastic transformation.
    Moore MA
    Ser Haematol; 1975; 8(4):11-27. PubMed ID: 1071283
    [No Abstract]   [Full Text] [Related]  

  • 17. A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
    Weinberger A; Benjamin D; Douer D; Barabash G; Djaldetti M; Pinkhas J
    Acta Haematol; 1978; 59(6):354-9. PubMed ID: 97894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indirubin in the treatment of chronic myelocytic leukemia (CML)--estimation of labelling index of bone marrow cells by 3H-TdR].
    You YC; Mi JX; Wan JH; Yang TY; Wang ZC; Qian LS
    Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):418-20. PubMed ID: 3482992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochemical variants of neutrophil leukocyte populations in chronic myelocytic leukaemia. A microspectrophotometric study of the change in the periodic acid-Schiff (PAS) reaction in blood and bone marrow neutrophils during busulfan treatment.
    Gahrton G; Brandt L; Franzén S; Nordén A
    Scand J Haematol; 1969; 6(6):365-72. PubMed ID: 4190430
    [No Abstract]   [Full Text] [Related]  

  • 20. [The determination of myeloid-committed stem cells in systemic disorders of myelopoiesis: implications for physiopathology, diagnosis and prognosis].
    Hinterberger W
    Acta Med Austriaca Suppl; 1981; 21():1-20. PubMed ID: 6949436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.